Univariate regression model for AT-AEs after starting TKI therapy
| . | AT-AEs: No . | AT-AEs: Yes . | IRR (95% CI) . | P* . |
|---|---|---|---|---|
| Continuous variables, mean (SD) | ||||
| Age, y | 48 (14) | 58 (14) | 1.06 (1.04-1.09) | <.001 |
| Serum albumin, g/dL | 4 (0.4) | 4 (0.4) | 0.40 (0.22-0.73) | .003 |
| BMI, kg/m2 | 28 (7) | 31 (9) | 1.05 (1.01-1.08) | .007 |
| Categorical variables, n (%) | ||||
| BMI ≥30, kg/m2 | ||||
| No | 330 (68) | 29 (63) | ||
| Yes | 155 (32) | 17 (37) | 1.54 (0.85-2.81) | .156 |
| TKI type | ||||
| IM400 | 66 (14) | 5 (11) | ||
| IM800 | 194 (40) | 9 (19) | 0.54 (0.18-1.60) | .265 |
| Nilotinib | 97 (20) | 11 (24) | 1.75 (0.61-5.04) | .298 |
| Dasatinib | 91 (19) | 15 (33) | 2.21 (0.80-6.09) | .124 |
| Ponatinib | 37 (8) | 6 (13) | 7.00 (2.14-22.94) | .001 |
| Prior hypertension | ||||
| No | 243 (50) | 18 (39) | ||
| Yes | 242 (50) | 28 (61) | 2.02 (1.12-3.65) | .020 |
| Prior diabetes | ||||
| No | 417 (86) | 36 (78) | ||
| Yes | 68 (14) | 10 (22) | 2.09 (1.04-4.22) | .039 |
| Prior smoking | ||||
| No | 377 (78) | 29 (63) | ||
| Yes | 108 (22) | 17 (37) | 2.05 (1.12-3.72) | .019 |
| Prior CAD | ||||
| No | 453 (93) | 34 (74) | ||
| Yes | 32 (7) | 12 (26) | 5.13 (2.66-9.91) | <.001 |
| Risk factors | ||||
| 0 | 106 (22) | 4 (9) | ||
| 1 | 161 (33) | 12 (26) | 2.44 (0.79-7.58) | .122 |
| 2 | 144 (30) | 16 (35) | 3.83 (1.28-11.45) | .016 |
| ≥3 | 74 (15) | 14 (30) | 7.34 (2.41-22.29) | <.001 |
| . | AT-AEs: No . | AT-AEs: Yes . | IRR (95% CI) . | P* . |
|---|---|---|---|---|
| Continuous variables, mean (SD) | ||||
| Age, y | 48 (14) | 58 (14) | 1.06 (1.04-1.09) | <.001 |
| Serum albumin, g/dL | 4 (0.4) | 4 (0.4) | 0.40 (0.22-0.73) | .003 |
| BMI, kg/m2 | 28 (7) | 31 (9) | 1.05 (1.01-1.08) | .007 |
| Categorical variables, n (%) | ||||
| BMI ≥30, kg/m2 | ||||
| No | 330 (68) | 29 (63) | ||
| Yes | 155 (32) | 17 (37) | 1.54 (0.85-2.81) | .156 |
| TKI type | ||||
| IM400 | 66 (14) | 5 (11) | ||
| IM800 | 194 (40) | 9 (19) | 0.54 (0.18-1.60) | .265 |
| Nilotinib | 97 (20) | 11 (24) | 1.75 (0.61-5.04) | .298 |
| Dasatinib | 91 (19) | 15 (33) | 2.21 (0.80-6.09) | .124 |
| Ponatinib | 37 (8) | 6 (13) | 7.00 (2.14-22.94) | .001 |
| Prior hypertension | ||||
| No | 243 (50) | 18 (39) | ||
| Yes | 242 (50) | 28 (61) | 2.02 (1.12-3.65) | .020 |
| Prior diabetes | ||||
| No | 417 (86) | 36 (78) | ||
| Yes | 68 (14) | 10 (22) | 2.09 (1.04-4.22) | .039 |
| Prior smoking | ||||
| No | 377 (78) | 29 (63) | ||
| Yes | 108 (22) | 17 (37) | 2.05 (1.12-3.72) | .019 |
| Prior CAD | ||||
| No | 453 (93) | 34 (74) | ||
| Yes | 32 (7) | 12 (26) | 5.13 (2.66-9.91) | <.001 |
| Risk factors | ||||
| 0 | 106 (22) | 4 (9) | ||
| 1 | 161 (33) | 12 (26) | 2.44 (0.79-7.58) | .122 |
| 2 | 144 (30) | 16 (35) | 3.83 (1.28-11.45) | .016 |
| ≥3 | 74 (15) | 14 (30) | 7.34 (2.41-22.29) | <.001 |
Analysis showing univariate Poisson regression models for new-onset vascular AEs (AT-AEs) after starting TKI therapy.
Bold indicates significant P values (P < .05).